Q4 report points to progress in the clinic for Gabather 22 februari, 2021 Last week, Gabather published its 2020 year-end report, which shows that the company is ramping up its clinical development with GT-002. Going forward the company will focus on studying the effects of its top c... LÄS MER!
Gabather – focus on CNS diseases 2 februari, 2021 Diseases of the central nervous system (CNS) and mental health issues represent a major burden on society, and there is considerable room for improvements of the current therapeutic alternatives. Swedish pharma... LÄS MER!
